Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.
Market Cap | 1.127 Billion | Shares Outstanding | 66.683 Million | Avg 30-day Volume | 388.021 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.25 |
Price to Revenue | 44.6583 | Debt to Equity | 0.0 | EBITDA | -82.864 Million |
Price to Book Value | 4.7738 | Operating Margin | -356.034 | Enterprise Value | 801.408 Million |
Current Ratio | 12.965 | EPS Growth | 0.192 | Quick Ratio | 12.566 |
1 Yr BETA | 1.0793 | 52-week High/Low | 18.96 / 9.84 | Profit Margin | -349.2638 |
Operating Cash Flow Growth | -49.2099 | Altman Z-Score | 9.8681 | Free Cash Flow to Firm | -57.384 Million |
Earnings Report | 2023-02-23 |
Please sign in first
none
45 Thousand total shares from 4 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
1,205,763 | 2023-01-03 | 5 | |
BALTHASER KEVIN CHIEF FINANCIAL OFFICER |
|
700 | 2023-01-01 | 1 |
MONAHAN JOSEPH CHIEF SCIENTIFIC OFFICER |
|
96,579 | 2022-12-15 | 6 |
|
434,455 | 2022-11-10 | 7 | |
|
9,856 | 2022-11-08 | 2 | |
MANION DOUGLAS J. PRES AND COO |
|
280,100 | 2022-08-01 | 2 |
CAWKWELL GAIL CHIEF MEDICAL OFFICER |
|
270,000 | 2022-07-01 | 2 |
|
20,257 | 2022-06-02 | 1 | |
|
28,051 | 2022-06-02 | 1 | |
|
39,822 | 2022-06-02 | 1 | |
|
54,454 | 2022-06-02 | 1 | |
|
47,504 | 2022-06-02 | 1 | |
|
39,822 | 2022-06-02 | 1 | |
RUFFO FRANK CHIEF FINANCIAL OFFICER |
|
201,883 | 2022-03-10 | 3 |
LOEROP JAMES CHIEF BUSINESS OFFICER |
|
200,000 | 2022-02-01 | 0 |
ALI-JACKSON KAMIL CHIEF LEGAL OFFICER |
|
160,214 | 2022-01-03 | 0 |
FORESITE CAPITAL MANAGEMENT III, LLC FORESITE CAPITAL FUND III, L.P. FORESITE CAPITAL MANAGEMENT IV, LLC FORESITE CAPITAL FUND IV, L.P. |
|
4,665,553 | 2021-11-01 | 0 |
GORDON DAVID N. CHIEF MEDICAL OFFICER |
|
147,447 | 2021-07-13 | 0 |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) |
|
No longer subject to file | 2019-06-27 | 0 |
SHANLER STUART CHIEF SCIENTIFIC OFFICER |
|
0 | 2019-03-01 | 0 |
POWALA CHRISTOPHER CHIEF REG & DEVELOP OFFICER |
|
272,163 | 2019-02-01 | 0 |
FAIR BRETT CHIEF COMMERCIAL OFFICER |
|
10,582 | 2019-02-01 | 0 |
|
571,471 | 2018-10-04 | 0 | |
|
No longer subject to file | 2017-08-21 | 0 | |
|
0 | 2017-06-15 | 0 | |
|
8,925,707 | 2017-02-28 | 0 | |
|
No longer subject to file | 2016-09-15 | 0 | |
|
0 | 2016-06-29 | 0 | |
|
2,314,942 | 2015-10-19 | 0 | |
SOFINNOVA VENTURE PARTNERS VIII, L.P. |
|
2,289,480 | 2015-10-13 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-04 18:20:05 -0500 | 2023-01-04 | S | 15,000 | $14.89 | d | 1,205,763 | direct | yes | 8.6671 | 15.7584 | 15.7584 | 6 | 0.0 | 1 | ||
2023-01-04 18:20:05 -0500 | 2023-01-03 | S | 23,382 | $15.19 | d | 1,222,381 | direct | yes | 8.6671 | 15.7584 | 15.7584 | 6 | 0.0 | 1 | ||
2023-01-04 18:20:05 -0500 | 2023-01-03 | S | 1,618 | $16.16 | d | 1,220,763 | direct | yes | 8.6671 | 15.7584 | 15.7584 | 6 | 0.0 | 1 | ||
2022-12-16 16:57:26 -0500 | 2022-12-15 | S | 5,000 | $15.88 | d | 96,386 | direct | yes | 3.0137 | 2.9452 | 4.726 | 4 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 22:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 21:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 21:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 20:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 20:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 19:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 19:15:04 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 18:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 18:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 17:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 17:15:04 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 16:45:04 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 16:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 15:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 15:15:04 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 14:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 14:15:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 13:45:03 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 13:15:04 UTC | 3.9119 | 0.4081 | 400000 |
ACLARIS THERAPEUTICS INC ACRS | 2023-01-31 12:45:03 UTC | 3.9119 | 0.4081 | 400000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | ACRS | -414.0 shares, $-447.12 | 2019-09-30 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | ACRS | -200.0 shares, $-3148.0 | 2022-09-30 | N-PORT |